Head-to-head evidence
deucravacitinib vs ICP-488
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT03611751 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.
Next expected readout: November 2026 · NCT05570955 (registry estimate)
ICP-488
Developed by Beijing InnoCare Pharma Tech Co.
NCT06109818 · Phase 2 · completed
The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.
Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · ICP-488's landscape